NeoGenomics, Inc. Cash and Restricted Cash
NeoGenomics, Inc. (NEO) had Cash and Restricted Cash of $145.54 million as of 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-07-28
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $145.54M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $146.14M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $159.62M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $164.12M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $145.54M 10-Q · filed 2026-07-28 |
| 2026-03-31 | $146.14M 10-Q · filed 2026-04-28 |
| 2025-12-31 | $159.62M 10-Q · filed 2026-07-28 |
| 2025-09-30 | $164.12M 10-Q · filed 2025-10-28 |
| 2025-06-30 | $154.72M 10-Q · filed 2026-07-28 |
| 2025-03-31 | $346.19M 10-Q · filed 2026-04-28 |
| 2024-12-31 | $367.01M 10-Q · filed 2026-07-28 |
| 2024-09-30 | $361.99M 10-Q · filed 2025-10-28 |
| 2024-06-30 | $355.08M 10-Q · filed 2025-07-29 |
| 2024-03-31 | $331.91M 10-Q · filed 2025-04-29 |
| 2023-12-31 | $342.49M 10-K · filed 2026-02-17 |
| 2023-09-30 | $306.24M 10-Q · filed 2024-11-05 |
| 2023-06-30 | $289.07M 10-Q · filed 2024-07-30 |
| 2023-03-31 | $275.61M 10-Q · filed 2024-04-30 |
| 2022-12-31 | $263.18M 10-K · filed 2026-02-17 |
| 2022-09-30 | $266.13M 10-Q · filed 2023-11-06 |
| 2022-06-30 | $283.64M 10-Q · filed 2023-08-08 |
| 2022-03-31 | $305.90M 10-Q · filed 2023-05-09 |
| 2021-12-31 | $316.83M 10-K · filed 2025-02-18 |
| 2021-09-30 | $343.73M 10-Q · filed 2022-11-08 |
| 2021-06-30 | $372.90M 10-Q · filed 2022-08-09 |
| 2021-03-31 | $623.09M 10-Q · filed 2022-05-09 |
| 2020-12-31 | $250.63M 10-K · filed 2024-02-20 |
| 2020-09-30 | $265.24M 10-Q · filed 2021-11-04 |
| 2020-06-30 | $331.31M 10-Q · filed 2021-08-09 |
| 2020-03-31 | $124.99M 10-Q · filed 2021-05-06 |
| 2019-12-31 | $173.02M 10-K · filed 2023-02-24 |
| 2019-09-30 | $178.89M 10-Q · filed 2020-10-29 |
| 2019-06-30 | $167.44M 10-Q · filed 2020-07-31 |
| 2019-03-31 | $13.20M 10-Q · filed 2020-04-29 |
| 2018-12-31 | $9.81M 10-K · filed 2022-02-25 |
| 2018-09-30 | $118.44M 10-Q · filed 2019-11-13 |
| 2018-06-30 | $9.44M 10-Q · filed 2019-08-07 |
| 2018-03-31 | $15.17M 10-Q · filed 2019-05-08 |
| 2017-12-31 | $12.82M 10-K · filed 2021-02-25 |
| 2016-12-31 | $12.53M 10-K · filed 2020-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |